Biohaven (BHVN) Stock Price, News & Analysis

Company Overview

Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neurological and neurodegenerative diseases. Established in 2013 and headquartered in New Haven, Connecticut, Biohaven leverages its proprietary portfolio of small molecule and peptide-based drug candidates to address areas of high unmet medical need. The company’s research and development efforts span a variety of neurological conditions, including migraine, rare genetic disorders, and other central nervous system (CNS) diseases.

Biohaven’s lead commercial product is rimegepant, marketed under the brand name Nurtec® ODT, an orally disintegrating tablet approved for the acute treatment of migraine and preventive therapy. In addition to rimegepant, the company is advancing zavegepant, an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist, through regulatory review in multiple regions. Beyond its migraine franchise, Biohaven’s pipeline encompasses novel candidates targeting neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as strategic collaborations to enhance development and commercial reach.

Throughout its history, Biohaven has engaged in key partnerships and licensing agreements to expand its global footprint. After an initial collaboration with Pfizer for the development and commercialization of rimegepant, Biohaven reacquired full worldwide rights to the asset, enabling direct control over its strategic positioning. The company maintains a presence in major markets across North America, Europe, and Asia, and continues to explore new alliances to support late-stage clinical programs and future launches.

Led by Founder and CEO Vlad Coric, M.D., Biohaven’s leadership team comprises seasoned executives with extensive experience in neuroscience, regulatory affairs, and global commercialization. The board and management emphasize a patient-centric approach and aim to bring transformative therapies to those affected by debilitating CNS disorders. With a strategy grounded in innovative science and disciplined execution, Biohaven is positioned to address significant unmet needs in neurology while building a sustainable franchise for long-term growth.

Key Stats

• Today's Range: $13.75 to $14.57
• 50-Day Range: $13.81 to $22.76
• 52-Week Range: $13.70 to $55.70
• Volume: 1.04 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $1.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.46
• Consensus Rating: Buy

Biohaven Stock Analysis - MarketRank™

Biohaven scored higher than 63% of companies evaluated by MarketBeat, and ranked 286th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Biohaven has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biohaven is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biohaven is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biohaven has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.68% of the float of Biohaven has been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Biohaven has recently increased by 0.55%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biohaven does not currently pay a dividend.

Dividend Growth

Biohaven does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.68% of the float of Biohaven has been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Biohaven has recently increased by 0.55%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.31

News Sentiment

Biohaven has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biohaven this week, compared to 8 articles on an average week.

Search Interest

17 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biohaven insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.60% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BHVN Stock Analysis - Frequently Asked Questions

How have BHVN shares performed this year?

Biohaven's stock was trading at $37.35 at the beginning of the year. Since then, BHVN stock has decreased by 63.0% and is now trading at $13.81.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) announced its earnings results on Monday, May, 12th. The company reported ($2.17) EPS for the quarter, missing analysts' consensus estimates of ($1.67) by $0.50.

When did Biohaven IPO?

Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHVN
• Previous Symbol: NASDAQ:BHVN
• CIK: 1935979
• Web: www.biohavenpharma.com
• Phone: 203-404-0410
• Fax: N/A
• Employees: 239
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $58.46
• High Stock Price Target: $76.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +317.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.07
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$846.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -257.07%
• Return on Assets: -164.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 102,110,000
• Free Float: 87,205,000
• Market Cap: $1.43 billion
• Optionable: Optionable
• Beta: 0.91